PRECISION BIOSCIENCES INC

DTIL · Nasdaq · United States

Share price · DTIL

$7.10-1.13 (-13.73%) 3M

close as of 2026-11-18 · 24h delayed · vol 370K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when DTIL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026-8.7%
  2. 5 Nov 2026+21.6%
  3. 4 Nov 2026+16.5%
  4. 28 Oct 2026+10.0%

    Nothing announced by DTIL that day or the session before.

  5. 23 Sep 2026-11.5%

    Nothing announced by DTIL that day or the session before.

  6. 22 Sep 2026+10.6%

    Nothing announced by DTIL that day or the session before.

  7. 18 Aug 2026+11.2%

    Nothing announced by DTIL that day or the session before.

  8. 7 Jul 2026+12.3%
  9. 28 May 2026-8.8%
  10. 9 Apr 2026+10.4%

    Nothing announced by DTIL that day or the session before.

Share of unusual movement by asset

For each asset, the share of DTIL's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Azercabtagene zapreleucel
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—31%
Sessions with no dated event—66%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1
CD19Cell therapy
Multiple SclerosisDiffuse Large B-Cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$13M$108M+ $0.1M short-term inv.$7.6M-$15M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$12M$112M+ $1.5M short-term inv.$33M-$13M operating cash flowreport ↗
2026-Q1$11M$13M$126M+ $1.8M short-term inv.$18M-$12M operating cash flowreport ↗
2025-Q3<$0.1M$13M$71M+ $0 short-term inv.$22M-$15M operating cash flowreport ↗
2025-Q2<$0.1M$13M$85M+ $0 short-term inv.$24M-$20M operating cash flowreport ↗
2025-Q1<$0.1M$14M$100M$21M-$19M operating cash flowreport ↗
2024-Q3$0.6M$13M$121M+ $2.5M short-term inv.$16M-$5.9M operating cash flowreport ↗
2024-Q2$50M$17M$124M—-$15M operating cash flowreport ↗
2024-Q1$18M$13M$138M—-$19M operating cash flowreport ↗
2023-Q3$13M$16M$122M$8.1M-$23M operating cash flowreport ↗
2023-Q2$20M$22M$138M$12M-$21M operating cash flowreport ↗
2023-Q1$8.8M$22M$158M$25M-$31M operating cash flowreport ↗
2022-Q3$7.4M$20M$212M$24M$29M operating cash flowreport ↗
2022-Q2$3.8M$23M$184M$31M-$24M operating cash flowreport ↗
2022-Q1$3.3M$20M$116M$28M-$29M operating cash flowreport ↗
2021-Q3$24M$26M$160M$11M-$24M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$34M$54M$137M+ $4.8M short-term inv.$11M-$66M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$69M$60M$108M+ $0.4M short-term inv.—-$58M operating cash flowreport ↗
2023-FY$49M$53M$117M$15M-$84M operating cash flowreport ↗
2022-FY$25M$84M$190M$28M-$46M operating cash flowreport ↗
2021-FY$116M$115M$144M$7.7M-$11M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 6 purchases ($63K), 9 sales ($459K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-10Scimeca Dario · Chief Legal OfficerOpen-market sale2,821$9.75$28KForm 4
2026-09-28Frankel Stanley · directorOpen-market purchase1,000$6.00$6KForm 4
2026-09-25Germano Geno J · directorOpen-market purchase2,609$6.28$16KForm 4
2026-09-25Brown Melinda · directorOpen-market purchase1,135$6.27$7KForm 4
2026-06-03Buehler Kevin · directorAward / grant (derivative)20,979——Form 4
2026-06-03Pire Shari Lisa · directorAward / grant (derivative)20,979——Form 4
2026-06-03Germano Geno J · directorAward / grant (derivative)20,979——Form 4
2026-06-03Frankel Stanley · directorAward / grant (derivative)20,979——Form 4